Biomea Fusion Stock Performance
| BMEA Stock | USD 2.53 0.01 0.40% |
The firm shows a Beta (market volatility) of 2.18, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Biomea Fusion will likely underperform. At this point, Biomea Fusion has a negative expected return of -0.62%. Please make sure to confirm Biomea Fusion's total risk alpha, skewness, rate of daily change, as well as the relationship between the maximum drawdown and accumulation distribution , to decide if Biomea Fusion performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Biomea Fusion has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's technical and fundamental indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return 0.4 | Five Day Return 2.02 | Year To Date Return (31.44) | Ten Year Return (85.12) | All Time Return (85.12) |
1 | Heres Why Biomea Fusion, Inc. Is Among the Best Diabetes Stocks to Buy Under 10 | 01/06/2025 |
2 | Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study | 01/07/2025 |
3 | Biomea Fusion to Become a Diabetes Obesity Medicines Company | 01/13/2025 |
4 | Biomea Fusion stock hits 52-week low at 3.58 amid sharp decline - MSN | 02/11/2025 |
5 | Biomea Fusion to Unveil New Icovamenib Data at the 18th International Conference on Advanced Technologies Treatments for Diabetes | 02/27/2025 |
6 | Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635 | 03/03/2025 |
7 | Acquisition by Thomas Butler of 305400 shares of Biomea Fusion at 9.8 subject to Rule 16b-3 | 03/05/2025 |
8 | Disposition of 159120 shares by Erdtmann Rainer M of Biomea Fusion at 7.5023 subject to Rule 16b-3 | 03/12/2025 |
9 | Disposition of 100000 shares by A2a Pharmaceuticals, Inc. of Biomea Fusion at 33.9931 subject to Rule 16b-3 | 03/17/2025 |
| Begin Period Cash Flow | 112.2 M | |
| Free Cash Flow | -100 M |
Biomea |
Biomea Fusion Relative Risk vs. Return Landscape
If you would invest 388.00 in Biomea Fusion on December 18, 2024 and sell it today you would lose (136.00) from holding Biomea Fusion or give up 35.05% of portfolio value over 90 days. Biomea Fusion is currently does not generate positive expected returns and assumes 4.3513% risk (volatility on return distribution) over the 90 days horizon. In different words, 38% of stocks are less volatile than Biomea, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Biomea Fusion Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Biomea Fusion's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Biomea Fusion, and traders can use it to determine the average amount a Biomea Fusion's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1428
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BMEA |
Estimated Market Risk
| 4.35 actual daily | 38 62% of assets are more volatile |
Expected Return
| -0.62 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.14 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Biomea Fusion is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Biomea Fusion by adding Biomea Fusion to a well-diversified portfolio.
Biomea Fusion Fundamentals Growth
Biomea Stock prices reflect investors' perceptions of the future prospects and financial health of Biomea Fusion, and Biomea Fusion fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Biomea Stock performance.
| Return On Equity | -1.05 | ||||
| Return On Asset | -0.56 | ||||
| Current Valuation | 12.94 M | ||||
| Shares Outstanding | 36.24 M | ||||
| Price To Book | 1.20 X | ||||
| EBITDA | (124.62 M) | ||||
| Net Income | (117.25 M) | ||||
| Cash And Equivalents | 149.63 M | ||||
| Cash Per Share | 5.11 X | ||||
| Total Debt | 10.3 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 16.46 X | ||||
| Book Value Per Share | 2.10 X | ||||
| Cash Flow From Operations | (96.59 M) | ||||
| Earnings Per Share | (4.01) X | ||||
| Market Capitalization | 91.32 M | ||||
| Total Asset | 199.93 M | ||||
| Retained Earnings | (248.82 M) | ||||
| Working Capital | 156.32 M | ||||
About Biomea Fusion Performance
By analyzing Biomea Fusion's fundamental ratios, stakeholders can gain valuable insights into Biomea Fusion's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Biomea Fusion has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Biomea Fusion has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.53) | (0.55) | |
| Return On Capital Employed | (0.82) | (0.78) | |
| Return On Assets | (0.53) | (0.55) | |
| Return On Equity | (0.80) | (0.76) |
Things to note about Biomea Fusion performance evaluation
Checking the ongoing alerts about Biomea Fusion for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Biomea Fusion help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Biomea Fusion generated a negative expected return over the last 90 days | |
| Biomea Fusion has high historical volatility and very poor performance | |
| Biomea Fusion has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (117.25 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Biomea Fusion currently holds about 149.63 M in cash with (96.59 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.11, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Biomea Fusion has a frail financial position based on the latest SEC disclosures | |
| Roughly 64.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Disposition of 100000 shares by A2a Pharmaceuticals, Inc. of Biomea Fusion at 33.9931 subject to Rule 16b-3 |
- Analyzing Biomea Fusion's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Biomea Fusion's stock is overvalued or undervalued compared to its peers.
- Examining Biomea Fusion's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Biomea Fusion's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Biomea Fusion's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Biomea Fusion's stock. These opinions can provide insight into Biomea Fusion's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Biomea Stock analysis
When running Biomea Fusion's price analysis, check to measure Biomea Fusion's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biomea Fusion is operating at the current time. Most of Biomea Fusion's value examination focuses on studying past and present price action to predict the probability of Biomea Fusion's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biomea Fusion's price. Additionally, you may evaluate how the addition of Biomea Fusion to your portfolios can decrease your overall portfolio volatility.
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |